Drug Use Patterns during the COVID-19 Pandemic: A Case Study at Persahabatan General Hospital

Authors

  • Fitri Nurhayati Instalasi Farmasi, Persahabatan General Hospital, East Jakarta, Jakarta, 13230, Indonesia ,
  • Dendhi Bagus Andriyanto Instalasi Farmasi, Persahabatan General Hospital, East Jakarta, Jakarta, 13230, Indonesia ,
  • Fadhila Putri Instalasi Farmasi, Persahabatan General Hospital, East Jakarta, Jakarta, 13230, Indonesia ,
  • Rara Merinda Puspitasari Universiti Kuala Lumpur, Royal College of Medicine Perak, Ipoh, Perak, 30450, Malaysia ,

DOI:

https://doi.org/10.35814/jifi.v21i1.1396

Keywords:

Drug use pattern, COVID-19 drug therapy, Persahabatan General Hospital

Abstract

The COVID-19 pandemic condition has encouraged healthcare practitioners to adapt and constantly work to meet the needs of those who require healthcare, including medication supply. This study aims to provide the drug use patterns prior to and throughout the COVID-19 pandemic. This retrospective descriptive study analyzed the drug use patterns of 10 fast-moving drugs obtained through purposive sampling, as well as all medications listed in COVID-19 guideline therapy at Persahabatan general hospital. The drug use data was derived from the quarterly data from 2019 through the second quarter of 2021. The result showed that there was an increase and variation in the sampled drug usage. The top-ranking classes that have shown an upward trend during the COVID-19 pandemic were Vitamin C 500 mg tablet, Vitamin C 200 mg injection, and Vitamin D3 5000 UI tablet. Meanwhile, non-COVID-19 medicines with reduced use include Cefotaxime 1 g, Cefixime 200 mg, and Docetaxel 20 mg. Therefore, it is necessary to analyze the drug utilization continuously and as frequently as feasible throughout the pandemic and plan in stages. Forecasting demand for medicines is essential for an effective medicinessupply chain, in particular in a pandemic context to avoid shortages or overstock.

References

Downloads

Published

2023-04-30

Issue

Vol. 21 No. 1 (2023): JIFI

Section

Articles

License

Licencing
All articles in Jurnal Ilmu Kefarmasian Indonesia are an open-access article, distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License which permits unrestricted non-commercial used, distribution and reproduction in any medium.

This licence applies to Author(s) and Public Reader means that the users mays :

  • SHARE:
    copy and redistribute the article in any medium or format
  • ADAPT:
    remix, transform, and build upon the article (eg.: to produce a new research work and, possibly, a new publication)
  • ALIKE:
    If you remix, transform, or build upon the article, you must distribute your contributions under the same license as the original.
  • NO ADDITIONAL RESTRICTIONS:
    You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.

It does however mean that when you use it you must:

  • ATTRIBUTION: You must give appropriate credit to both the Author(s) and the journal, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.

You may not:

  • NONCOMMERCIAL: You may not use the article for commercial purposes.

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.